No profile data available.
CollPlant Biotechnologies Ltd. (CLGN) is a healthcare company in the various healthcare equipment manufacturing industry, based in Rehovot, Israel, with about 39 full-time employees.
It reported revenue of $2.37 million for fiscal year 2025, up 360.4% from fiscal year 2024, and net income of -$11.49 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $108,000, down 39.7% from a year before. United States was its largest region in fiscal year 2025, with 92% of revenue. Its market capitalization was $6.64 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
CollPlant Biotechnologies reported $2.37 million in revenue for fiscal year 2025, up 360.4% from $515,000 in fiscal year 2024. In Q2 2026 revenue was $108,000.
United States: 92% of revenue by region in fiscal year 2025, followed by Europe and Other (4%).
$6.64 million as of October 9, 2026.
Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Harvard Bioscience, Inc. (HBIO), Elutia Inc. (ELUT), Aethlon Medical, Inc. (AEMD), Therma Bright Inc. (TBRIF).